Imidex and Spesana Form Strategic Partnership to Impact Early Lung Cancer Detection and Patient Outcomes
2024年7月11日 - 10:00PM
Spesana, a leader in personalized medicine technology for
clinicians, diagnostic labs and pharmaceutical companies including
the oncology specialty, and Imidex, developer of VisiRad XR, an
FDA-cleared computer aided detection technology that identifies
lung nodules and masses in chest X-rays, are thrilled to announce
their partnership to transform lung cancer detection and patient
care.
Through a collaborative clinical study design,
Imidex and Spesana will combine their technologies to measure the
impact of AI on improving lung nodule and mass detection. VisiRad
XR, Imidex’s cutting-edge AI detection algorithm, will be
integrated with Spesana’s state-of-the-art medical data and
clinical workflow platform to study how many additional lung
nodules and masses can be detected in existing chest X-rays during
usual care. Using the data, Imidex and Spesana aim to quantify
downstream lung cancer detection rates, identify at-risk patients
for clinical trials through screening, and evaluate the potential
use of liquid biopsies resulting from nodule detection on chest
X-rays.
Lung cancer is the leading cause of cancer deaths
in the United States, with most cases detected too late for
successful treatment. VisiRad XR’s computer vision technology
provides a powerful second-read capability for radiologists, arming
them with 83% sensitivity in detecting lung nodules and masses,
findings that are frequently overlooked. By collaborating with
Spesana to bring VisiRad XR to a broader set of providers and
patients, Imidex aims to demonstrate the capability of chest x-ray
based AI to be the front end for lung nodule screening and
detection.
Spesana’s platform is designed to accelerate the
movement of patients to the right specialists through a unified
medical record, enhancing clinical workflows with real-time
collaboration and decision support based on real-world data and
molecular diagnostics results. Spesana’s Authorize product is
designed to reduce time and friction in the prior authorization
process, therefore increasing the speed to optimal care. By
integrating VisiRad XR’s AI insights, Spesana aims to empower
healthcare providers with comprehensive patient views, intelligent
diagnostic order intake, and digital results, ensuring seamless and
efficient care pathways.
"Imagine a world where lung cancer is detected
early, treatment begins sooner, and patients have a fighting chance
for a better prognosis," said Carla Balch, CEO of Spesana. “Our
partnership now extends the comprehensive nature of precision
medicine by adding imaging diagnostics to our deep existing
molecular diagnostic capabilities.”
"Imidex is deploying our leading FDA 510(k) cleared
algorithm for lung nodule and mass detection to improve the
screening of potential future lung cancer patients,” said Wes
Bolsen, CEO of Imidex. “Our collaboration with Spesana will equip
healthcare providers and pharmaceutical companies with the tools
they need to identify lung nodules earlier, improve patient
outcomes, and optimize healthcare resources."
For more information, please contact:
IMIDEX3513 Brighton Blvd, Suite
456Denver, CO 80216media@imidex.com
Spesana1331 Union Avenue, Suite
1000Memphis, TN 38104Info@Spesana.com